Latest Tokyo Brief coverage on DAIICHI SANKYO COMPANY, LIMITED, tracking filings, financial news, and market signals from Japan.
TSE:4568
Northern TK Venture has appealed to the Tokyo High Court after the district court threw out its entire ¥203.3 billion damages claim against Daiichi Sankyo over a blocked Fortis Healthcare tender offer, and the pharma company now says the earnings impact is under review rather than nil.
A Tokyo court dismissed every claim in Northern TK Venture's three-year suit against Daiichi Sankyo, including a demand that swelled from ¥20bn to ¥203.3bn over a blocked Fortis Healthcare tender offer, though an appeal remains possible.
Enhertu and Datroway drove a 21.1% revenue jump for Daiichi Sankyo and prompted an upgraded sales and operating-profit outlook, yet a jump in the effective tax rate to 24.9% means the company actually cut its full-year net profit guidance by ¥9bn.
Current holdings disclosed by tracked funds.